Phase 3 Clinical Trials With Primary Completion Dates in June 2021
This is a list of Phase 3 trials with primary completion dates in June 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALDX | Aldeyra Therapeutics, Inc. | 2021-06-01 | Phase 3 | NCT04207736 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. |
| AMRN | Amarin Corporation plc | 2021-06-01 | Phase 3 | NCT04460651 | PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial |
| CORT | Corcept Therapeutics Incorporated | 2021-06-01 | Phase 3 | NCT04308590 | Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
| DCPH | Deciphera Pharmaceuticals, Inc. | 2021-06-01 | Phase 3 | NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib |
| EXEL | Exelixis, Inc. | 2021-06-01 | Phase 3 | NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy |
| FULC | Fulcrum Therapeutics, Inc. | 2021-06-01 | Phase 3 | NCT04511819 | Losmapimod Safety and Efficacy in COVID-19 |
| MDWD | MediWound Ltd. | 2021-06-01 | Phase 3 | NCT02278718 | A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care |
| OTLK | Outlook Therapeutics, Inc. | 2021-06-01 | Phase 3 | NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
| RIGL | Rigel Pharmaceuticals, Inc. | 2021-06-01 | Phase 3 | NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| SCPH | scPharmaceuticals Inc. | 2021-06-01 | Phase 3 | NCT03458325 | Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure |
| SCYX | SCYNEXIS, Inc. | 2021-06-01 | Phase 3 | NCT04029116 | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) |
| SMMT | Summit Therapeutics Inc. | 2021-06-01 | Phase 3 | NCT03595566 | To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
| SMMT | Summit Therapeutics Inc. | 2021-06-01 | Phase 3 | NCT03595553 | Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
| SPPI | Spectrum Pharmaceuticals, Inc. | 2021-06-01 | Phase 3 | NCT01478542 | OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine |